{"id":"https://openalex.org/W2781950702","doi":"https://doi.org/10.5167/uzh-89551","title":"EORTC-EANO-ESMO-Konferenz 2013: die vIII-Mutationsvariante des epidermalen Wachstumsfaktorrezeptors \u2013 EGFRvIII als Angriffspunkt f\u00fcr die Immuntherapie des Glioblastoms","display_name":"EORTC-EANO-ESMO-Konferenz 2013: die vIII-Mutationsvariante des epidermalen Wachstumsfaktorrezeptors \u2013 EGFRvIII als Angriffspunkt f\u00fcr die Immuntherapie des Glioblastoms","publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W2781950702","doi":"https://doi.org/10.5167/uzh-89551","mag":"2781950702"},"language":"de","primary_location":{"id":"pmh:oai:www.zora.uzh.ch:89551","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/89551/1/LOonko_1303_52-53_EANO_-_EGFRvIII_als_Angriffspunkt_f%C3%BCr_Immuntherapie_bei_Glioblastom_%28Weller_Stupp%29.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/89551/1/LOonko_1303_52-53_EANO_-_EGFRvIII_als_Angriffspunkt_f%C3%BCr_Immuntherapie_bei_Glioblastom_%28Weller_Stupp%29.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Weller, M; Stupp, R (2013). EORTC-EANO-ESMO-Konferenz 2013: die vIII-Mutationsvariante des epidermalen Wachstumsfaktorrezeptors \u2013 EGFRvIII als Angriffspunkt f\u00fcr die Immuntherapie des Glioblastoms. Leading Opinions H\u00e4matologie & Onkologie:52-53.","raw_type":"Journal Article"},"volume":null,"type":"article","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.zora.uzh.ch/id/eprint/89551/1/LOonko_1303_52-53_EANO_-_EGFRvIII_als_Angriffspunkt_f%C3%BCr_Immuntherapie_bei_Glioblastom_%28Weller_Stupp%29.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017177249","display_name":"Michael Weller","orcid":"https://orcid.org/0000-0002-1748-174X","observed_orcids":["https://orcid.org/0000-0002-1748-174X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Weller, M","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5053052330","display_name":"Roger Stupp","orcid":"https://orcid.org/0000-0002-5483-3118","observed_orcids":["https://orcid.org/0000-0002-5483-3118"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stupp, R","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.34181629,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"52","last_page":"53"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfrviii","display_name":"EGFRvIII","score":0.9520000219345093},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9570000171661377},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.8619999885559082},{"id":"https://openalex.org/keywords/cancer-vaccines","display_name":"cancer vaccines","score":0.5540000200271606},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.6669999957084656}],"concepts":[{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.4986002445220947},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4666338562965393}],"mesh":[],"locations_count":4,"locations":[{"id":"pmh:oai:www.zora.uzh.ch:89551","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/89551/1/LOonko_1303_52-53_EANO_-_EGFRvIII_als_Angriffspunkt_f%C3%BCr_Immuntherapie_bei_Glioblastom_%28Weller_Stupp%29.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/89551/1/LOonko_1303_52-53_EANO_-_EGFRvIII_als_Angriffspunkt_f%C3%BCr_Immuntherapie_bei_Glioblastom_%28Weller_Stupp%29.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Weller, M; Stupp, R (2013). EORTC-EANO-ESMO-Konferenz 2013: die vIII-Mutationsvariante des epidermalen Wachstumsfaktorrezeptors \u2013 EGFRvIII als Angriffspunkt f\u00fcr die Immuntherapie des Glioblastoms. Leading Opinions H\u00e4matologie & Onkologie:52-53.","raw_type":"Journal Article"},{"id":"pmh:oai:www.zora.uzh.ch:20.500.14742/99939","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/handle/20.500.14742/99939","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Weller, M., & Stupp, R. (2013). EORTC-EANO-ESMO-Konferenz 2013: die vIII-Mutationsvariante des epidermalen Wachstumsfaktorrezeptors \u2013 EGFRvIII als Angriffspunkt f\u00fcr die Immuntherapie des Glioblastoms. Leading Opinions. H\u00e4matologie & Onkologie, 52\u201353.","raw_type":"Journal Article"},{"id":"doi:10.5167/uzh-89551","doi":"https://doi.org/10.5167/uzh-89551","is_oa":true,"landing_page_url":"https://doi.org/10.5167/uzh-89551","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},{"id":"mag:2781950702","doi":null,"is_oa":false,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/89551/1/LOonko_1303_52-53_EANO_-_EGFRvIII_als_Angriffspunkt_f%C3%BCr_Immuntherapie_bei_Glioblastom_%28Weller_Stupp%29.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:www.zora.uzh.ch:89551","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/89551/1/LOonko_1303_52-53_EANO_-_EGFRvIII_als_Angriffspunkt_f%C3%BCr_Immuntherapie_bei_Glioblastom_%28Weller_Stupp%29.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/89551/1/LOonko_1303_52-53_EANO_-_EGFRvIII_als_Angriffspunkt_f%C3%BCr_Immuntherapie_bei_Glioblastom_%28Weller_Stupp%29.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Weller, M; Stupp, R (2013). EORTC-EANO-ESMO-Konferenz 2013: die vIII-Mutationsvariante des epidermalen Wachstumsfaktorrezeptors \u2013 EGFRvIII als Angriffspunkt f\u00fcr die Immuntherapie des Glioblastoms. Leading Opinions H\u00e4matologie & Onkologie:52-53.","raw_type":"Journal Article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7073573211","https://openalex.org/W2322556147","https://openalex.org/W2404365847","https://openalex.org/W2766168238","https://openalex.org/W2056679169","https://openalex.org/W2558690325","https://openalex.org/W4240962932","https://openalex.org/W7061578973","https://openalex.org/W2086978682","https://openalex.org/W173055122"],"abstract_inverted_index":{"Immunologische":[0],"Therapieverfahren":[1],"werden":[2],"beim":[3],"Glioblastom":[4,38],"seit":[5],"Langem":[6],"als":[7],"Alternative":[8],"zu":[9],"klassischen":[10],"Ans\u00e4tzen":[11],"der":[12,26],"Krebstherapie":[13],"diskutiert.":[14],"Nach":[15],"erfolgversprechenden":[16],"Phase-II-Daten":[17],"wird":[18],"Rindopepimut,":[19],"eine":[20],"Vakzine,":[21],"die":[22,24],"spezifisch":[23],"Struktur":[25],"EGFRvIII-Mutation":[27],"nachahmt,":[28],"nun":[29],"in":[30],"einer":[31],"Phase-III-Studie":[32],"(ACT":[33],"IV)":[34],"bei":[35],"neu":[36],"diagnostiziertem":[37],"gepr\u00fcft.":[39]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-01-12T00:00:00"}